[go: up one dir, main page]

SE2050559A1 - PD-1 as a predictive marker for therapy in cancer - Google Patents

PD-1 as a predictive marker for therapy in cancer

Info

Publication number
SE2050559A1
SE2050559A1 SE2050559A SE2050559A SE2050559A1 SE 2050559 A1 SE2050559 A1 SE 2050559A1 SE 2050559 A SE2050559 A SE 2050559A SE 2050559 A SE2050559 A SE 2050559A SE 2050559 A1 SE2050559 A1 SE 2050559A1
Authority
SE
Sweden
Prior art keywords
therapy
cancer
predictive marker
determining
breast cancer
Prior art date
Application number
SE2050559A
Inventor
Tullberg Axel Stenmark
Erik Holmberg
Per Karlsson
Original Assignee
Khs Biomedinvent Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khs Biomedinvent Ab filed Critical Khs Biomedinvent Ab
Priority to SE2050559A priority Critical patent/SE2050559A1/en
Priority to AU2021272986A priority patent/AU2021272986A1/en
Priority to PCT/US2021/032080 priority patent/WO2021231641A1/en
Priority to US17/998,334 priority patent/US20230375549A1/en
Priority to EP21803206.8A priority patent/EP4149616A4/en
Priority to CA3183417A priority patent/CA3183417A1/en
Publication of SE2050559A1 publication Critical patent/SE2050559A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

There is provided a method for treating breast cancer comprising the steps:a) obtaining a tissue sample of a tumour from a breast cancer patient, b) determining the expression level of PD-1 in the sample,c) determining that the expression level is below a threshold level,d) providing intensified treatment as radiotherapy treatment, systemic therapy or mastectomy to the patient.
SE2050559A 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer SE2050559A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer
AU2021272986A AU2021272986A1 (en) 2020-05-13 2021-05-12 PD-1 as a predictive marker for therapy in cancer
PCT/US2021/032080 WO2021231641A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer
US17/998,334 US20230375549A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer
EP21803206.8A EP4149616A4 (en) 2020-05-13 2021-05-12 PD-1 AS A PREDICTIVE MARKER FOR CANCER THERAPY
CA3183417A CA3183417A1 (en) 2020-05-13 2021-05-12 Pd-1 as a predictive marker for therapy in cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer

Publications (1)

Publication Number Publication Date
SE2050559A1 true SE2050559A1 (en) 2021-11-14

Family

ID=78816986

Family Applications (1)

Application Number Title Priority Date Filing Date
SE2050559A SE2050559A1 (en) 2020-05-13 2020-05-13 PD-1 as a predictive marker for therapy in cancer

Country Status (1)

Country Link
SE (1) SE2050559A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145493A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2017140826A1 (en) * 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
WO2018160841A1 (en) * 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018191660A1 (en) * 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012145493A1 (en) * 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
WO2017140826A1 (en) * 2016-02-18 2017-08-24 Institut Gustave Roussy Methods and kits for predicting the sensitivity of a subject to immunotherapy
WO2018160841A1 (en) * 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2018191660A1 (en) * 2017-04-14 2018-10-18 Genentech, Inc. Diagnostic and therapeutic methods for cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lu L et al., "Elevated T cell activation score is associated with improved survival of breast cancer", Breast Cancer Res Treat, 2017, 164(3):689-696 *
Yeong J et al., "Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer", J Immunother Cancer, 2019, 7:34 *

Similar Documents

Publication Publication Date Title
ES2721639T3 (en) Method for diagnosis, prognosis and treatment of breast cancer metastasis
MX365421B (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf.
MX2021002006A (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition.
EA202092113A1 (en) METHOD FOR PRODUCING P300 AND / OR CBP MODULATORS
WO2019103998A3 (en) Promoting trained immunity with therapeutic nanobiologic compositions
MX2021003214A (en) Therapeutic and diagnostic methods for bladder cancer.
SE2050559A1 (en) PD-1 as a predictive marker for therapy in cancer
MX2021011799A (en) Semaphorin-4d antagonists for use in cancer therapy.
MX2025005696A (en) Methods of determining cancer therapy effectiveness
MX2025011364A (en) Method of treating early breast cancer with ribociclib in combination with an aromatase inhibitor
CA3243978A1 (en) Bcl-2 inhibitors and aurora kinase inhibitors for treating cancer
Pan et al. A novel approach of INTRABEAM intraoperative radiotherapy for nipple-sparing mastectomy with breast reconstruction
MX2020013883A (en) Oncology treatments using zinc agents.
CA3263227A1 (en) Identification and methods of treatment of breast cancer
IL320743A (en) Method of treating prostate cancer
WO2022259242A8 (en) Combined treatment for cancer
WO2022221464A3 (en) Method and compositions for preventing tumor development and metastasis
BR112022018238A2 (en) METHOD OF TREATMENT OF A CANCER IN A SUBJECT
IL308684A (en) Methods of treating breast cancer
MX2023009374A (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib.
Kashirina et al. Breast Cancer Surgery, History and Current State: a Literature Review
LI et al. Expression and clinical significance of ALG3 as a potential biomarker in bladder cancer
Kang et al. WNT3A Upregulates the RIP1/HIF-1α/GDF-15 Pathway to Induce EMT and Thereby Increase Colorectal Cancer Cell Migration and Invasion
MX2023009999A (en) Methods of reducing risk of prostate cancer progression.
Trigolosov et al. Internal mammary nodes metastases for breast cancer: whether the morphological verification is necessary?

Legal Events

Date Code Title Description
NAV Patent application has lapsed